This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Street, S. E.A. Articles by Smyth, M. J. Search for Related Content PubMed PubMed Citation Articles by Street, S. E.A. Articles by Smyth, M. J.

Host Perforin Reduces Tumor Number but Does Not Increase Survival in Oncogene-Driven Mammary Adenocarcinoma

¹ Cancer Immunology Program, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia; ² Department of Immunology, Monash University, Alfred Medical Research and Education Precinct, Melbourne, Victoria, Australia; and ³ Department of Oncology and Neuroscience, "G. D'Annunzio" University of Chieti-Pescara, Chieti, Italy

Requests for reprints: Mark J. Smyth, Cancer Immunology Program, Peter MacCallum Cancer Centre, Locked Bag 1, A'Beckett Street, East Melbourne, 8006 Victoria, Australia. Phone: 61-39656-3728; Fax: 61-39656-1411; E-mail: mark.smyth{at}petermac.org.

The concept of tumor immune surveillance has been supported by several recent studies in mice which show that immune effector mechanisms suppress hematologic malignancy. However, because the most common forms of human cancer are epithelial in origin, and comparatively very little data supports the immune surveillance of epithelial malignancies, we have chosen to evaluate the role of perforin-mediated cytotoxicity in the prevention of BALB/c Her2/neu-induced mammary cancer. Interestingly, perforin significantly delayed the onset of mammary tumorigenesis and reduced the number of mammary tumors without improving survival. Natural killer cell, but not CD8⁺ T cell, depletion resulted in a similar phenotype to perforin deficiency in this regard. Histologic analysis further indicated that the effect of perforin was most evident during the earliest stages of carcinogenesis rather than prior to or during the hyperplastic phase. This data suggests that perforin may mediate some suppression of epithelial carcinogenesis by intervening early in the tumor development process. [Cancer Res 2007;67(11):5454–60]

This article has been cited by other articles:

				C. J. Chan, D. M. Andrews, N. M. McLaughlin, H. Yagita, S. Gilfillan, M. Colonna, and M. J. Smyth DNAM-1/CD155 Interactions Promote Cytokine and NK Cell-Mediated Suppression of Poorly Immunogenic Melanoma Metastases J. Immunol., January 15, 2010; 184(2): 902 - 911. [Abstract] [Full Text] [PDF]

				P. Bolitho, S. E. A. Street, J. A. Westwood, W. Edelmann, D. MacGregor, P. Waring, W. K. Murray, D. I. Godfrey, J. A. Trapani, R. W. Johnstone, et al. Perforin-mediated suppression of B-cell lymphoma PNAS, February 24, 2009; 106(8): 2723 - 2728. [Abstract] [Full Text] [PDF]